Navigation Links
Flu institute a booster shot for Wisconsin biotech stature

and unavailable for comment, but Bugher said the avian flu vaccine is up there with stem cells in terms of breakthrough technology. The avian flu is being talked about almost every day in the international news, noted Bugher, who is working to develop a second University Research Park campus on Madisons Far West side. If Wisconsin can become the centerpiece for avian flu research, and scientist Yo......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 03/15/06


Page: 1 2 3

Related biology technology :

1. UW-Madison approves new research institute
2. GE Healthcare partners with genomics institute
3. Leading cancer institute to install three TomoTherapy systems
4. Japanese institute installs Imago system
5. New biomedical institute aims to unite business and academia in SE Wisconsin
6. Japanese institute will develop for UWs Croquet platform
7. To be a player in the "Knowledge Economy," Wisconsin needs more tech workers
8. Federal bioenergy lab will give Wisconsin a chance to shine
9. Breaking down Wisconsins angel capital numbers
10. Innovation featured in NE Wisconsin Roundtable
11. Visions: Broderick says Wisconsin should be in top third in venture capital
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Flu institute booster shot for Wisconsin biotech stature

Breaking Biology News(10 mins):New science estimates carbon storage potential of US lands 2Vermicompost from pig manure grows healthy hibiscus 2XRC Medical Imaging Announces Rapid Test Results 14182 1XRC Medical Imaging Announces Rapid Test Results 14182 2Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 1Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 2Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 3Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 4Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 5Abbotts XIENCE V 28R 29 Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long Term Safety Results in SPIRIT III Trial 5024 6Dalton Pharma Services Adds Formulation Development Services 57793 1Dalton Pharma Services Adds Formulation Development Services 57793 2